Literature DB >> 7908915

Recombinant CD40 ligand exerts potent biologic effects on T cells.

W C Fanslow1, K N Clifford, M Seaman, M R Alderson, M K Spriggs, R J Armitage, F Ramsdell.   

Abstract

Murine and human CD40 ligand (CD40L) were recently cloned, expressed, and shown to possess potent activity on human and murine B cells, including stimulation of proliferation and Ig secretion in the presence of cytokines. In addition to its action on B lymphocytes, this report demonstrates that CD40L induced both CD4+ and CD8+ T cells isolated from murine lymphoid tissues to proliferate in the presence of submitogenic dosages of Con A, PHA, CD3 mAb, and TCR-alpha beta mAb. The presence of CD40L during suboptimal TCR stimulation resulted in increased expression of the activation Ags IL-2R alpha and CD69 and increased IL-2 production. Taken together, these results show that CD40L is a potent activator of murine T cells and suggest that CD40L is involved in the regulation of T cell function mediated through T:T cell interaction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908915

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  The biology of the human ligand for CD40.

Authors:  M K Spriggs; W C Fanslow; R J Armitage; J Belmont
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

Review 2.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Antiviral immune responses in CTLA4 transgenic mice.

Authors:  C Zimmermann; P Seiler; P Lane; R M Zinkernagel
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1.

Authors:  A Ihata; S Watabe; S Sasaki; A Shirai; J Fukushima; K Hamajima; J Inoue; K Okuda
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

5.  Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.

Authors:  Raphaël F Rousseau; Ettore Biagi; Aurélie Dutour; Eric S Yvon; Michael P Brown; Tiffany Lin; Zhuyong Mei; Bambi Grilley; Edwina Popek; Helen E Heslop; Adrian P Gee; Robert A Krance; Uday Popat; George Carrum; Judith F Margolin; Malcolm K Brenner
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

6.  Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes.

Authors:  David H Wagner; Gisela Vaitaitis; Richard Sanderson; Michelle Poulin; Cathleen Dobbs; Kathryn Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  Requirement for CD40 ligand, CD4(+) T cells, and B cells in an infectious mononucleosis-like syndrome.

Authors:  J W Brooks; A M Hamilton-Easton; J P Christensen; R D Cardin; C L Hardy; P C Doherty
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

8.  Humoral immune responses in CD40 ligand-deficient mice.

Authors:  B R Renshaw; W C Fanslow; R J Armitage; K A Campbell; D Liggitt; B Wright; B L Davison; C R Maliszewski
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

9.  Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand.

Authors:  D C Parker; D L Greiner; N E Phillips; M C Appel; A W Steele; F H Durie; R J Noelle; J P Mordes; A A Rossini
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

10.  CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation.

Authors:  E Castigli; F W Alt; L Davidson; A Bottaro; E Mizoguchi; A K Bhan; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.